PDS 0101

Drug Profile

PDS 0101

Alternative Names: PDS 101; PDS0101; PDS0101A; PDS0101B; Versamune-HPV

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PDS Biotechnology Corporation
  • Class Cancer vaccines; Papillomavirus vaccines; Peptide vaccines
  • Mechanism of Action Cytokine stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Cervical intraepithelial neoplasia

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Cervical-intraepithelial-neoplasia in USA (SC, Injection)
  • 10 Jul 2017 PDS Biotechnology enters into a clinical trial collaboration agreement with Merck for Head and neck cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater)
  • 10 Jul 2017 PDS Biotechnology and Merck plan a phase II trial for Head and neck cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top